U.S., Dec. 12 -- ClinicalTrials.gov registry received information related to the study (NCT07277413) titled 'A Study of IDE892 as Monotherapy and Combination in MTAP-deleted Advanced Solid Tumors' on Nov. 13.
Brief Summary: This is a multicenter clinical study to evaluate the safety, efficacy, and Pharmacokinetics (PK) of IDE892 as monotherapy and in combination with other agents including IDE397 in participants with methylthioadenosine phosphorylase (MTAP)-deleted advanced solid tumors within indications of interest.
Study Start Date: Dec. 15
Study Type: INTERVENTIONAL
Condition:
NSCLC Adenocarcinoma
Gastroesophageal Cancer (GC)
Gastric Adenocarcinoma
Adenocarcinoma of Esophagus
Squamous Cell Car. - Esophagus
Urothelial Carcinoma (UC)...